Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Open this folder and view contentsChapter 5: The international supply of praziquantel*
Open this folder and view contentsChapter 6: Demand for praziquantel and national distribution*
Open this folder and view contentsChapter 7: Prices and production costs of praziquantel*
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

Abstract

International Strategies for Tropical Disease Treatments: Experiences with praziquantel, edited by Michael R. Reich, with contributions from: Michael R. Reich, Ramesh Govindaraj, Karin Dumbaugh, Bong-min Yang, Agnes Brinkmann, and Sameh El-Saharty.

This report identifies national and international policies that have facilitated or hindered the availability of praziquantel, the drug of choice for all forms of schistosomiasis occurring in humans. The report gives particular attention to questions of access for people in the world's poorest countries in Africa where schistosomiasis is endemic. The analysis of praziquantel illustrates more general problems in the design of national and international policies for tropical disease products, and suggests strategies for future research and action. The report’s seven chapters are: Chapter 1: Policies for praziquantel; Chapter 2: Bayer & E. Merck: Discovery and development of praziquantel; Chapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea; Chapter 4: Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation; Chapter 5: The international supply of praziquantel; Chapter 6: Demand for praziquantel and national distribution; and Chapter 7: Prices and production costs for praziquantel.

This research project was carried out through the Takemi Program in International Health, at the Harvard School of Public Health (665 Huntington Avenue, Boston, MA, USA 02115), with the financial support of the Edna McConnell Clark Foundation.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014